STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
trthaber.com - 2026-10-15
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarc...